You Did Not Order the Wrong Formulation—But They Are Different Medications
Metoprolol tartrate and metoprolol succinate are NOT the same drug—they are different salt formulations with distinct pharmacokinetic profiles and dosing schedules, though both contain the same active moiety (metoprolol) and are clinically appropriate for most indications. The key difference is that metoprolol tartrate is an immediate-release formulation requiring twice-daily dosing, while metoprolol succinate is an extended-release formulation designed for once-daily administration 1.
Key Pharmacological Differences
Metoprolol tartrate:
- Immediate-release formulation
- Dosed 2-3 times daily (typically every 6-12 hours)
- Rapid onset with higher peak plasma concentrations
- Greater fluctuation in drug levels throughout the day 2
Metoprolol succinate:
- Extended-release (CR/XL) formulation using multiple-unit pellet system
- Dosed once daily
- More consistent plasma levels with lower peak concentrations but higher trough levels
- Near zero-order release kinetics over 24 hours 3, 2
Clinical Equivalence and Guideline Support
Both formulations are guideline-endorsed and clinically equivalent for most cardiovascular indications. The 2013 ACC/AHA STEMI guidelines explicitly state that clinicians can "transition over next 2 to 3 days to twice-daily dosing of metoprolol tartrate or to daily metoprolol succinate" 1. Similarly, heart failure guidelines list both formulations with their respective dosing schedules 4, 5, 6.
Dosing Equivalence
- Metoprolol tartrate 25-50 mg twice daily ≈ Metoprolol succinate 50-100 mg once daily
- Target doses: Tartrate up to 200 mg/day (divided), Succinate up to 200 mg once daily 1, 4, 6
When Each Formulation May Be Preferred
Metoprolol succinate advantages:
- Superior medication adherence with once-daily dosing
- More stable hemodynamic effects throughout 24 hours 2
- Proven mortality benefit in heart failure (MERIT-HF trial used succinate) 7, 6
- Better sustained beta-blockade at end of dosing interval 2
Metoprolol tartrate advantages:
- Available in IV formulation for acute settings 1, 8
- Lower cost and wider availability 9
- Easier dose titration with smaller incremental changes
- Faster washout if adverse effects occur
Critical Clinical Considerations
For heart failure specifically: The landmark MERIT-HF trial that demonstrated mortality reduction used metoprolol succinate (CR/XL), not tartrate 7, 6. The COMET trial showed metoprolol tartrate was inferior to carvedilol for heart failure mortality 10. If your patient has heart failure with reduced ejection fraction, metoprolol succinate is the evidence-based choice 4, 5, 6.
For post-MI and hypertension: Both formulations are acceptable, with guidelines listing both options 1. The choice depends on patient preference for dosing frequency and cost considerations.
Acute hemodynamic effects are identical: When readministered during chronic therapy, both formulations produce parallel decreases in cardiac index, increases in systemic vascular resistance, and similar effects on stroke volume—the differences are purely pharmacokinetic, not pharmacodynamic 11.
Practical Resolution
You did not order the "wrong" medication—you ordered a clinically appropriate beta-blocker. However, you should:
- Verify the indication: If heart failure with reduced EF, succinate is preferred based on trial evidence
- Check the dose: Ensure equivalent total daily dosing (tartrate requires BID dosing)
- Communicate with the other provider: Clarify which formulation will be continued to avoid confusion
- Document clearly: Specify "metoprolol tartrate" or "metoprolol succinate" rather than just "metoprolol" to prevent substitution errors
The most common pitfall is assuming they are interchangeable without dose adjustment—remember that tartrate must be dosed twice daily while succinate is once daily, even though the total daily dose may be similar 1, 4, 6.